Roche gains FDA authorization for automated mass spectrometry
The cobas pro i 601 and Ionify Gabapentin combination adds therapeutic drug monitoring to the US offering.

Roche has reported FDA De Novo authorization for cobas pro i 601 with the Ionify Gabapentin assay. Part of the cobas Mass Spec solution, the combination extends testing into therapeutic drug monitoring.
The company aims to combine mass spectrometry with automated, standardized routine-laboratory workflows. Traditional methods frequently require specialist staff and manual steps, according to the announcement. The gabapentin test joins existing US applications for vitamin D and steroid hormones.
Context and evidence
Roche also cites an authorized Predetermined Change Control Plan allowing potential expansion by up to 22 Ionify assays when requirements are met. Those additional tests are explicitly not yet available. An authorized development pathway is not immediate launch of the entire future menu.
What it means
Clinical laboratories can assess how a complex analytical technique fits routine operations. Reductions in staffing effort and turnaround times must be evaluated against local workflows and verifiable operational data.
Primary source: Original announcement. This report is based on company statements, not an independent clinical assessment.
More from Regulation
AI illustrationFDA clears AI software for coronary CT analysis
Syngo.CT Coronary Cockpit analyzes plaque and supports intervention planning. The clearance applies to the US market.
AI illustrationHugo surgical robot gains US clearance for general surgery
Medtronic expands the US indications for its robotic-assisted surgery platform; clearance is not proof of superior outcomes.
AI illustrationPhilips submits helium-free 3T MRI platform to the FDA
BlueSeal Horizon is under review, not cleared; “helium-free” describes operation with helium sealed inside the magnet.